Journal article icon

Journal article

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.

Abstract:

AIMS: The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial. METHODS AND RESULTS: EVOLVE recruited 291 patients from 29 centres. At six months, IVUS-assessed in-stent net volume obstruction was 3.40 ± 5.0...

Expand abstract

Actions


Access Document


Publisher copy:
10.4244/eijv9i3a52

Authors


Meredith, IT More by this author
Verheye, S More by this author
Weissman, NJ More by this author
Barragan, P More by this author
Expand authors...
Journal:
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Volume:
9
Issue:
3
Pages:
308-315
Publication date:
2013-07-05
DOI:
EISSN:
1969-6213
ISSN:
1774-024X
URN:
uuid:4535cfb3-640a-462a-b5ae-b106f475f45c
Source identifiers:
414771
Local pid:
pubs:414771

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP